DEVELOPMENT, CHARACTERIZATION AND PHARMACOKINETIC EVALUATION OF OPTIMIZED VILDAGLIPTIN SUSTAINED RELEASE MATRIX TABLET USING BOX-BEHNKEN DESIGN

SANJAY KUMAR GUPTA; SRADHANJALI PATRA

doi:10.22159/ijap.2024v16i1.48052

Authors

SANJAY KUMAR GUPTA Department of Pharmaceutical Sciences, Utkal University, Bhubaneswar, Odisha https://orcid.org/0000-0001-9627-0440
SRADHANJALI PATRA Department of Pharmaceutical Sciences, Utkal University, Bhubaneswar, Odisha

DOI:

https://doi.org/10.22159/ijap.2024v16i1.48052

Keywords:

Vildagliptin, Box–behnken, Checkpoint, FTIR, DSC, Counter plots

Abstract

Objective: The principal objective of this research was to develop and optimize cost-effective sustained-release Vildagliptin (VLN) tablets using the wet granulation method.

Methods: The tablets were prepared by the non-aqueous wet granulation method. A Box-Behnken design was used to study the effect of the independent variables, i.e., HPMC K100 M, Eudragit RSPO and PVP K30, on the dependent variables swelling index, in vitro drug release at 8 and 12 h. The drug's physiochemical properties were investigated using ultraviolet (UV), Fourier transform infrared (FTIR) and differential scanning calorimetry (DSC). The hardness, thickness, weight variation, content uniformity, swelling index, and in vitro drug release study of the formulated tablets were all evaluated. The optimized formulation Opt-VLD-SR was evaluated for pharmacokinetic parameters like AUC, C_max,t_maxand MRT.

Results: The FTIR and DSC studies confirmed that no interaction occurred between the drug, polymers and excipients. The crystalline nature of VLN remained unchanged in the optimised formulation tablet, according to DSC studies. With the optimal concentration of both polymers, formulation Opt-VLN delayed drug release for up to 12 h. The formulated Optimized Sustained-release tablets (Opt-VLD-SR) showed significantly lower Cmax±3.01ng/ml) than conventional IR tablets (256.17±8.02ng/ml). In the pharmacokinetic study, the MRT for Optimized-VLD-SR is (7.40h) showed a better result than the Vildagliptin IR marketed product (3.70 h.), which leads to higher bioavailability of Vildagliptin.

Conclusion: Sustained release tablets of VLN with a combination of diffusion and erosion-controlled drug release mechanisms have been successfully developed.

Downloads

Download data is not yet available.

References

Naik JB, Waghulde MR. Development of vildagliptin loaded Eudragit® microspheres by screening design: in vitro evaluation. J Pharm Investig. 2018;48(6):627-37. doi: 10.1007/s40005-017-0355-3.

Waghulde M, Rajput R, Mujumdar A, Naik J. Production and evaluation of vildagliptin-loaded poly(dl-lactide) and poly(dl-lactide-glycolide) micro/nanoparticles: response surface methodology approach. Drying Technol. 2019;37(10):1265-76. doi: 10.1080/07373937.2018.1495231, PMID 1495231.

Derosa G, Maffioli P. Efficacy and safety profile evaluation of acarbose alone and in association with other antidiabetic drugs: a systematic review. Clin Ther. 2012 Jun;34(6):1221-36. doi: 10.1016/j.clinthera.2012.04.012, PMID 22560622.

Kuksal A, Tiwary AK, Jain NK, Jain S. Formulation and in vitro, in vivo evaluation of extended-release matrix tablet of zidovudine: influence of the combination of hydrophilic and hydrophobic matrix formers. AAPS PharmSciTech. 2006 Jan 3;7(1):E1. doi: 10.1208/pt070101, PMID 16584139, PMCID PMC2750708.

Naveentaj S, Muzib YI, Radha R. Design and optimization of fluconazole-loaded pharmacosome gel for enhancing transdermal permeation and treating fungal infections through box-behnken design. Int J App Pharm. 2023;15(1, Jan):131-40. doi: 10.22159/Ijap.2023v15i1.46413.

Singh S, Verma D, Mirza MA, Das AK, dudeja M, Anwer MK. Development and optimization of ketoconazole loaded nano-transpersonal gel for vaginal delivery using box-behnken design: in vitro, ex vivo characterization and antimicrobial evaluation. J Drug Deliv Sci Technol. 2017;39:95-103. doi: 10.1016/j.jddst.2017.03.007.

Fu Y, Kao WJ. Drug release kinetics and transport mechanisms of non-degradable and degradable polymeric delivery systems. Expert Opin Drug Deliv. 2010 Apr;7(4):429-44. doi: 10.1517/17425241003602259, PMID 20331353, PMCID PMC2846103.

Sahoo, Satyajit, Malviya, Kirti, Makwana, Ami, Mohapatra, Prasanta, Asit, Sahu. Formulation, optimization and evaluation of sublingual film of enalapril maleate using 32 full factorial design. Int J Appl Pharm. 2021;13:178-86. doi: 10.22159/Ijap.2021v13i1.

Siepmann J, Peppas NA. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Deliv Rev. 2001 Jun 11;48(2-3):139-57. doi: 10.1016/s0169-409x(01)00112-0, PMID 11369079.

Ferreira SL, Bruns RE, Ferreira HS, Matos GD, David JM, Brandao GC. Box-Behnken design: an alternative for the optimization of analytical methods. Anal Chim Acta. 2007;597(2):179-86. doi: 10.1016/j.aca.2007.07.011, PMID 17683728.

Kothiya OM, Patel BA, Patel KN, Patel MM. Formulation and characterization of sustained release matrix tablets of ivabradine using 32 full factorial design. Int J App Pharm. 2018;10(1):59-66. doi: 10.22159/ijap.2018v10i1.21584.

Audel P, Noori MH, Poudel BK, Shakya S, Bhatta P, Lamichhane S. Influence of different grades and concentrations of hydroxypropyl methylcellulose on the release of metformin hydrochloride. World J Pharm Sci. 2014;2:966-80.

Mukhopadhyay D. Optimization of process parameters for the economical generation of biogas from raw vegetable wastes under the positive influence of plastic materials using response surface methodology. J Biochem Technol. 2013;4:549-53.

Mujtaba A, Ali M, Kohli K. Statistical optimization and characterization of pH-independent extended-release drug delivery of cefpodoxime proxetil using box–behnken design. Chem Eng Res Des. 2014;92(1):156-65. doi: 10.1016/j.cherd.2013.05.032.

Velpandian T, Jaiswal J, Bhardwaj RK, Gupta SK. Development and validation of a new high-performance liquid chromatographic estimation method of meloxicam in biological samples. J Chromatogr B Biomed Sci Appl. 2000 Feb 11;738(2):431-6. doi: 10.1016/s0378-4347(99)00537-x, PMID 10718662.

Djebbar M, Chaffai N, Bouchal F. Development of floating tablets of metformin HCl by thermoplastic granulation. Part II: in vitro evaluation of the combined effect of acacia gum/HPMC on biopharmaceutical performances. Adv Pharm Bull. 2020 Jul;10(3):399-407. doi: 10.34172/apb.2020.048, PMID 32665898.

Huang YB, Tsai YH, Lee SH, Chang JS, Wu PC. Optimization of pH-independent release of nicardipine hydrochloride extended-release matrix tablets using response surface methodology. Int J Pharm. 2005 Jan 31;289(1-2):87-95. doi: 10.1016/j.ijpharm.2004.10.021, PMID 15652202.

Myers RH, Montgomery DC, Vining GG, Borror CM, Kowalski SM. Response surface methodology: a retrospective and literature survey. J Qual Technol. 2004;36(1):53-77. doi: 10.1080/00224065.2004.11980252.

Sravani K, Priyanka D, Sravani R, Reddy KS, Kumar DV. Formulation and evaluation of vildagliptin sustained release matrix tablets. Int J Curr Pharm Res. 2014;6(4):69-75.

Sangana R, Mittal H, Barsainya S, Hoermann A, Borde P, Naik S. Therapeutic equivalence of vildagliptin 100 mg once daily modified release to 50 mg twice daily immediate release formulation: an open-label, randomized, two-period, single and multiple-dose, 6 d crossover study. Diabetes Metab Syndr. 2022 Mar;16(3):102438. doi: 10.1016/j.dsx.2022.102438, PMID 35272176.

Dole K, He YL, Ligueros M, Zhang Y. A randomized, open-label, three period, cross-over study to evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of two new LAF237 100 mg and 150-mg modified release formulations in patients with type 2 diabetes; 2007.